GSK predatory abuse on hospital antibiotics in France

Conseil de la concurrence decision (80 pages in French, PDF) finding that GlaxoSmithKline has abused a dominant position though predatory pricing in 1999 and 2000 of Zinnat (an antibiotic for surgery-induced infections) and its bundling with injectable Zovirax (an antiviral drug for surgery-induced infections). The Conseil found that GSK's conduct had the anti-competitive object of slowing down the entry of generic alternatives to injectable Zinnat when its supplementary protection certificate expired in 1999.

Update, April 2008: Reversed on appeal.

For further information or advice please contact Franck Latrémolière.

Filed under Article 82, Conseil de la concurrence, France, Healthcare, Pharmaceuticals.

Reckon LLP is an economics consultancy with expertise in data analysis, economic regulation and competition law.

About Reckon